3 years ago

Treatment of prurigo with methotrexate: a multicenter retrospective study of 39 cases Running head: Treatment of prurigo with methotrexate

P. Joly, S. Debarbieux, P. Wolkenstein, O. Chosidow, S. Ingen-Housz-Oro, M. A. Richard, L. Misery, M. Beylot-Barry, T. Klejtman
Background Prurigo is a common primary pruritic condition. Treatment is challenging. Methotrexate (MTX) is effective for the treatment of pruriginous dermatoses, but its use in prurigo has been little studied. Objectives To investigate the efficacy and safety of MTX in the treatment of difficult-to-treat prurigo. Methods Patients from six university dermatology departments treated with MTX between 2006 and 2016 for difficult-to-treat prurigo (i.e. with failure to conventional therapies) were included in this retrospective multicenter study. Patients with other pruritic dermatoses were excluded. Clinical efficacy was recorded after 3, 6, and 12 months of treatment: 1/ subjective efficacy, i.e. evaluation of the pruritus by the patient and 2/ objective efficacy, i.e. assessment of cutaneous lesions by the physician: complete or almost complete remission (CR) (healing of lesions), partial remission (PR) (incomplete improvement of lesions), or failure (no improvement or worsening). The overall response rate (ORR) included CR and PR. Results Thirty-nine patients with previous failure of topical steroids, H1-antihistamine drugs, or phototherapy were included. The median weekly dose of MTX was 15 mg (range 5-25 mg). The median follow-up was 16 months (2-108). The mean time between onset of MTX and objective efficacy was 2.4 +/- 1.2 months and the mean duration of response was 19 +/- 15 months. The ORR was 91% at three months (n=36, CI95% [81.2%-100.8%], CR 44%), 94% at six months (n=32, CI95% [85.7%-102.2%], CR 56%), and 89% at 12 months (n=28, CI95% [77.4%-100.6%], CR 57%). Seven patients stopped MTX because of failure, and five because of the discovery of hepatocarcinoma (n=1), elevated transaminases (n=1), infectious pneumonitis (n=1), or gastrointestinal symptoms (n=2). Conclusion MTX is a therapeutic option in difficult-to-treat prurigo. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/jdv.14646

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.